Results 41 to 50 of about 39,069 (192)
The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design
ABSTRACT The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single‐center, randomized, double‐blind, placebo‐controlled trial designed to test whether clazkizumab, an interleukin‐6 (IL‐6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo.
Sebastian E. Sattui +11 more
wiley +1 more source
Krisanaklan reduces CFTR‐dependent intestinal chloride and fluid secretion by inhibiting the Na+,K+‐ATPase and K+ channels in epithelial cells. Consequently, this natural, plant‐derived product may limit secretory diarrhea caused by a diverse array of microbial pathogens. However, by dissipating the transmembrane Na+ gradient, Krisanaklan also inhibits
Tessa A. Groeneweg +4 more
wiley +1 more source
Rotavirus symptomatic infection among unvaccinated and vaccinated children in Valencia, Spain
Background Human group A rotavirus is the leading cause of severe acute gastroenteritis in young children worldwide. Immunization programs have reduced the disease burden in many countries. Vaccination coverage in the Autonomous Region of Valencia, Spain,
Raúl Pérez-Ortín +5 more
doaj +1 more source
Stewardship of Molecular Diagnostics in Transplant Viral Infections
ABSTRACT The transplant environment requires special considerations when testing for viral infections as immunosuppression results in atypical infection profiles. Microbes otherwise considered commensals or causing mild disease can lead to severe infections in transplant environments. Therefore, guidelines tend to recommend broader microbial testing in
Scott Sugden +3 more
wiley +1 more source
ABSTRACT Objectives The primary objectives of this study are to (1) summarise the current landscape of ETEC vaccine development by describing, characterising and comparing ETEC vaccine candidates in clinical development, (2) assess key characteristics of the phases 1, 2 and 3 clinical trials that have been designed to evaluate ETEC vaccines in ...
Vaidehi Nafade +4 more
wiley +1 more source
Bee products as alternatives in the treatment of viral infections
Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba +3 more
wiley +1 more source
Prevalence of Four Enteropathogens with Immunochromatographic Rapid Test in the Feces of Diarrheic Calves in East and Southeast of Turkey [PDF]
In this study, fecal specimens taken from 192 diarrheic and 14 healthy calves (2-40 days old) were examined for the presence of bacterial and parasitic agents. Fecal samples from diarrheic calves with the four immunochromatographic rapid tests were 92.7%
Hasan Içen1, Neval Berrin Arserim2, Nurettin IŞIK3, Cumali Özkan4* and Abdullah Kaya4
doaj
Rotavirus is a leading cause of gastroenteritis in children under 5 years of age. It is known that neurological manifestations like seizures, encephalopathy and encephalitis can rarely be seen due to rotavirus infections. Cerebellar involvement is
Cem Paketçi +7 more
doaj +1 more source
Timeline of events ABSTRACT Moderate‐to‐severe ulcerative colitis can be effectively treated with JAK‐1 inhibition, but platelet counts should be closely monitored, especially in active disease. We confirmed immune‐mediated thrombocytopenia (ITP) in one of our patients after the initiation of filgotinib. Whether this was drug‐induced is uncertain.
M. J. van der Hoff +2 more
wiley +1 more source
The choline‐binding protein A (CbpA) was shown to mediate adhesion of probiotic Ligilactobacillus salivarius strains to human intestinal epithelial cells (IECs). A knockout mutant lacking the CbpA protein derived from the immunomodulatory porcine strain L. salivarius FFIG58 was obtained. The CbpA is a key surface protein of L.
Yoshiya Imamura +13 more
wiley +1 more source

